English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Accumulating evidence suggests tumor protein 53 (p53) promotes correct cellular differentiation. Thus, mutant  TP53  may be more frequent in tumors with irregular differentiation. This study investigated whether  TP53  mutations were more frequent in diffuse large B cell lymphoma (DLBCL) that lacked the B cell lineage marker CD19. Sixteen CD19 negative and 78 CD19 positive DLBCL were sequenced for  TP53  mutations. Twenty nine tumors had  TP53  mutations and were associated with poorer survival. Mutant  TP53  was more frequent in CD19 negative lymphomas (81% versus 21%, p < 0.0001). Analysis of other B cell markers revealed a lack of paired box 5 (PAX5) in CD19 positive lymphomas with mutant  TP53  (50%), which was more frequent compared to tumors with wild-type  TP53  (15%, p = 0.002). In summary, DLBCL lacking CD19 or PAX5 expression were more likely to have mutant  TP53 , suggesting irregular B cell marker phenotypes are associated with  TP53  mutation.

Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression